Low-Dose Aspirin as Primary Prophylaxis for Cardiovascular Events in Rheumatoid Arthritis: An Italian Multicentre Retrospective Study

Table 2

Univariate analysis: factors associated with cardiovascular event occurrence.

Features	HR (CI)
Sex (F)	1.21 (0.43–3.09)	0.693
Age > 60 years	4.75 (1.98–11.35)	0.0005
RF+	0.91 (0.52–1.62)	0.752
ACPA+	1.80 (0.92–3.52)	0.08
Erosion	1.11 (0.56–2.20)	0.76
SDAI > 11	2.40 (1.03–5.59)	0.0004
Smoke	0.58 (0.28–1.18)	0.1334
Hypertension	19.3 (4.65–80.18)	0.0001
Diabetes	2.14 (1.01–4.52)	0.046
Hypercholesterolemia	5.13 (2.33–11.3)	<0.0001
Obesity	1.29 (0.56–2.95)	0.543
Biological treatment	0.42 (0.22–0.82)	0.01
HCQ	0.12 (0.04–0.39)	0.0005
MTX	0.99 (0.98–1.01)	0.940
Statins	3.68 (1.88–7.23)	0.0001
ASA	0.15 (0.05–0.51)	0.002
Cumulative dose of steroids	1 (0.99–1)	0.186

HR: hazard ratio; CI: confidence interval; RF: rheumatoid factor; ACPA: anti-citrullinated cyclic peptide antibodies; SDAI: Simplified Disease Activity Index; HAQ-DI: Health Assessment Questionnaire-Disability Index; HCQ: hydroxychloroquine; MTX: methotrexate; ASA: acetylsalicylic acid. A value < 0.05 was considered for factors associated with cardiovascular event occurrence (positive predictor if HR > 1, negative if HR < 1).